We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PTAB Invalidates AbbVie’s Humira Dosing Patent — Again
PTAB Invalidates AbbVie’s Humira Dosing Patent — Again
The PTO’s Patent Trial and Appeal Board once again ruled that a patent for AbbVie’s Humira was invalid and unpatentable, responding to additional challenges by Boehringer Ingelheim.